Salvat was present at The Bio International Convention 2019, at Philadelphia, US.

Salvat was present at the world’s largest pharmaceutical biotechnology event: The Bio International Convention 2019, which took place this year in Philadelphia (USA), from June 3rd to 6th, where meetings were held with companies from the pharmaceutical industry from all over the world. The aim was to explore new business opportunities for licensing our products and offering our development and manufacturing services.

 

 

Salvat participated in the CPhI North America Congress

Salvat participated in the CPhI North America Congress, which annually gathers the most important companies of North America. This year it was held in Chicago, where we held many meetings with other pharmaceutical companies to explore opportunities that allow us to continue developing our activity in the United States.

Salvat and Pharmaloop participated in the CPhI Worldwide Congress

Salvat and Pharmaloop participated in the CPhI Worldwide Congress, which annually gathers the most important companies in the pharmaceutical world. This year it was held in Madrid, where both companies had the opportunity to hold many meetings with other pharmaceutical companies to explore opportunities that allow us to increase our activities internationally.

 

Laboratorios Salvat has participated in the consortium created for the development of the INDREYE research project “Innovative solutions for the treatment and diagnosis of dry eye syndrome”

Laboratorios Salvat has participated in the consortium created for the development of the INDREYE research project “Innovative solutions for the treatment and diagnosis of dry eye syndrome” funded by the Spanish National Program of Public-Private Cooperation, subprogram INNPACTO, 2012 call. This program is co-financed by the European Union through the European regional development fund (ERDF/FEDER).

Laboratorios SALVAT maintains the rating of ‘VERY GOOD’ in the PROFARMA call in 2018

On July 26, 2018, the Spanish Ministry of Industry, Commerce and Tourism, through the General Secretariat of Industry and Small and Medium Enterprises resolved to grant Laboratorios Salvat its classification within Group A: Companies with significant research activity with own pharmaceutical production plant or its own basic or preclinical R & D center, with the rating “VERY GOOD”.

We are proud to continue to deserve this qualification, which distinguishes the companies with the highest Pharmaceutical Research & Development investments in the country.

Salvat launches Ekzem

We present Ekzem®, the first and only medicinal product indicated for the treatment of eczematous otitis externa
Up until the recent release of Ekzem®, launched by SALVAT this January 2017, there was no medicinal product in Spain specifically indicated for the treatment of eczematous otitis externa. Up until now, otorhinolaryngologists, primary care physicians and other specialists saw the need to employ steroid preparations that weren’t specifically designed to treat acute outbreaks of intense itching, oedema, redness and flaking, which are characteristic of eczematous otitis externa; a very common diagnosis in appointments with both ear specialists and the family doctor.
Eczematous otitis externa is an extremely common pathology, of which there are no incidence or prevalence data in our community. Whilst it is not considered to be a serious disease, eczema of the ear can have a significant negative impact on the quality of the life of those who are affected by it, mainly due to the intensity, maliciousness or duration of the itching that it causes. The usual scraping of the canal with cotton swabs, or by other inadequate means, can cause injury which can lead to infections of the skin of the external auditory canal. Therefore, for acute outbreaks, specialists recommend treating the symptoms properly and quickly through the use of mid-strength corticosteroids, and also recommend using emollients and moisturisers for those who suffer from the problem chronically.
Ekzem® contains 0.025% fluocinolone acetonide, a mid-strength corticosteroid which is capable of producing an anti-inflammatory, anti-pruritic and vasocontrictive short term effect. In the mandatory clinical trial – multicentre, randomised and double-blind versus placebo – conducted by Laboratorios SALVAT to obtain the new indication for this corticosteroid, it was shown that Ekzem® reduces the intensity of the itching by an average of 40% in the hours immediately after treatment. By the fifth day of treatment, having applied twice daily on the affected ear, the intensity of the pruritus is reduced by more than 70%. At the end of the study, the clinical signs are reduced by 84% in the case of erythema; 83% in the case of oedema; 85.2% with regards to flaking and 85.2% in the otoscopic signs considered as a whole. After this period, there is an 81.8% reduction in the scale of itching.
Each Ekzem® container contains 30 single-dose vials for a symptomatic treatment of up to 7-8 days. In the case of bilateral eczema, a vial will need to be used every 12 hours in each of the eczematous ears. The vials come grouped in strips of 15, each protected by an aluminium sachet that will keep the active substance stable for up to 2 years, meaning it can be used in any outbreaks that occur throughout this period.